Potentiation of (-)-epigallocatechin-3-gallate-induced apoptosis by bortezomib in multiple myeloma cells

Acta Biochimica et Biophysica Sinica

Volumn 41, Issue 12, 2009, Pages 1018-1026

  Wang, Qing ^a   Li, Juan ^a   Gu, Jingli ^a   Huang, Beihui ^a   Zhao, Ying ^a   Zheng, Dong ^a   Ding, Yan ^a   Zeng, Lijin ^a  

^a SUN YAT SEN UNIVERSITY   (China)

Author keywords

( ) epigallocatechin 3 gallate; Apoptosis; Bortezomib; Multiple myeloma; NF B

Indexed keywords

ANTINEOPLASTIC AGENT; BORONIC ACID DERIVATIVE; BORTEZOMIB; CATECHIN; DRUG DERIVATIVE; EPIGALLOCATECHIN GALLATE; MESSENGER RNA; PYRAZINE DERIVATIVE; TRANSCRIPTION FACTOR RELA;

APOPTOSIS; ARTICLE; CHEMISTRY; DRUG EFFECT; GENETICS; HUMAN; METABOLISM; MULTIPLE MYELOMA; PATHOLOGY; POLYMERASE CHAIN REACTION; TEA; TUMOR CELL LINE; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BLOTTING, WESTERN; BORONIC ACIDS; CATECHIN; CELL LINE, TUMOR; HUMANS; MULTIPLE MYELOMA; POLYMERASE CHAIN REACTION; PYRAZINES; RNA, MESSENGER; TEA; TRANSCRIPTION FACTOR RELA;

EID: 71949106168     PISSN: 16729145     EISSN: 17457270     Source Type: Journal    
DOI: 10.1093/abbs/gmp094     Document Type: Article

References (32)

1. Myeloma Trialists' Collaborative Group. Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: A n overview of 6,633 patients from 27 randomized trials. J Clin Oncol 1998, 16: 3832-3842.
2. Schwarzenbach H. Expression of MDR1/P-glycoprotein, the multidrug resistance protein MRP, and the lung-resistance protein LRP in multiple myeloma. Med Oncol 2002, 19: 87-104.
3. Sen T, Moulik S, Dutta A, Choudhury PR, Banerji A, Das S and Roy M, et al. Multifunctional effect of epigallocatechin-3-gallate (EGCG) in downregulation of gelatinase-A (MMP-2) in human breast cancer cell line MCF-7. Life Sci 2009, 84: 194-204.
4. Nagarajan S, Nagarajan R, Braunhut SJ, Bruno F, McIntosh D, Samuelson L and Kumar J. Biocatalytically oligomerized epicatechin with potent and specific anti-proliferative activity for human breast cancer cells. Molecules 2008, 13: 2704-2716.
5. Sasaki N, Morisaki T, Hashizume K, Yao T, Tsuneyoshi M, Noshiro H and Nakamura K, et al. Nuclear factor-kB p65 (RelA) transcription factor is constitutively activated in human gastric carcinoma tissue. Clin Cancer Res 2001, 7: 4136-4142.
6. Ma G, Tabanca N, Husnu Can Baser K, Kirimer N, Pasco DS, Khan IA and Khan SI. Inhibition of NF-kB-mediated transcription and induction of apoptosis in human breast cancer cells by epoxypseudoisoeugenol-2-methyl butyrate. Cancer Chemother Pharmacol 2009, 63: 673-680.
7. Baeuerle PA and Baichwal VR. NF-kB as a frequent target for immunosuppressive and anti-inflammatory molecules. Adv Immunol 1997, 65: 111-137.
8. Nakahara C, Nakamura K, Yamanaka N, Baba E, Wada M, Matsunaga H and Noshiro H, et al. Cyclosporin-A enhances docetaxel-induced apoptosis through inhibition of nuclear factor-kB activation in human gastric carcinoma cells. Clin Cancer Res 2003, 9: 5409-5416.
9. Wu JT and Kral JG. The NF-kB/IkB signaling system: A molecular target in breast cancer therapy. J Surg Res 2005, 123: 158-169.
10. Ahmad N, Gupta S and Mukhtar H. Green tea polyphenol epigallocatechin- 3-gallate differentially modulates nuclear factor kB in cancer cells versus normal cells. Arch Biochem Biophys 2000, 376: 338-346.
11. Surh YJ, Chun KS, Cha HH, Han SS, Keum YS, Park KK and Lee SS. Molecular mechanisms underlying chemopreventive activities of antiinflammatory phytochemicals: Down-regulation of COX-2 and iNOS through suppression of NF-kB activation. Mutat Res 2001, 480-481: 243-268.
12. Gupta S, Hastak K, Afaq F, Ahmad N and Mukhtar H. Essential role of caspases in epigallocatechin-3-gallate-mediated inhibition of nuclear factor kB and induction of apoptosis. Oncogene 2004, 23: 2507-2522.
13. Zhang LC, Shen SR, Sun SL, Yang JG, He GQ and Yu HN. Growth inhibition of prostate cancer cells by epigallocatechin-3-gallate in the presence of Zn2+ in vitro. Fen Zi Xi Bao Sheng Wu Xue Bao 2008, 41: 443-449.
14. Chen XL, Wang Q, Cao LQ, Huang XH, Fu XH, Tan HX and Zhen MC, et al. Epigallocatechin-3-gallate induces apoptosis in human hepatocellular carcinoma cells. Zhonghua Yi Xue Za Zhi 2008, 88: 2524-2528.
15. Wu H, Yokoyama T, Zhu B, Shimoishi Y, Murata Y and Nakamura Y. (2)-Epigallocatechin-3-gallate potentiates the cytotoxicity induced by benzyl isothiocyanate and hydrogen peroxide in human Jurkat T lymphocytes. Biosci Biotechnol Biochem 2008, 72: 3034-3037.
16. Chuu CP, Chen RY, Kokontis JM, Hiipakka RA and Liao S. Suppression of androgen receptor signaling and prostate specific antigen expression by (2)-epigallocatechin-3-gallate in different progression stages of LNCaP prostate cancer cells. Cancer Lett 2009, 275: 86-92.
17. Han DW, Matsumura K, Kim B and Hyon SH. Time-dependent intracellular trafficking of FITC-conjugated epigallocatechin-3-O-gallate in L-929 cells. Bioorg Med Chem 2008, 16: 9652-9659.
18. Berger SJ, Gupta S, Belfi CA, Gosky DM and Mukhtar H. Green tea constituent (2)-epigallocatechin-3-gallate inhibits topoisomerase I activity in human colon carcinoma cells. Biochem Biophys Res Commun 2001, 288: 101-105.
19. Yin Z, Henry EC and Gasiewicz TA. (2)-Epigallocatechin-3-gallate is a novel Hsp90 inhibitor. Biochemistry 2009, 48: 336-345.
20. He J, Tohyama Y, Yamamoto K, Kobayashi M, Shi Y, Takano T and Noda C, et al. Lysosome is a primary organelle in B cell receptormediated apoptosis: A n indispensable role of Syk in lysosomal function. Genes Cells 2005, 10: 23-35.
21. Hastak K, Gupta S, Ahmad N, Agarwal MK, Agarwal ML and Mukhtar H. Role of p53 and NF-kB in epigallocatechin-3-gallate-induced apoptosis of LNCaP cells. Oncogene 2003, 22: 4851-4859.
22. Zhang H and Guo R. The establishment of three human myeloma cell lines. Chin J Cell Biol 1998, 2: 88.
23. Chaturvedi MM, Mukhopadhyay A and Aggarwal BB. Assay for redoxsensitive transcription factor. Methods Enzymol 2000, 319: 585-602.
24. Chou TC and Talalay P. Quantitative analysis of dose-effect relationships: T he combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984, 22: 27-55.
25. Noda C, He J, Takano T, Tanaka C, Kondo T, Tohyama K and Yamamura H, et al. Induction of apoptosis by epigallocatechin-3- gallate in human lymphoblastoid B cells. Biochem Biophys Res Commun 2007, 362: 951-957.
26. Yang GY, Liao J, Kim K, Yurkow EJ and Yang CS. Inhibition of growth and induction of apoptosis in human cancer cell lines by tea polyphenols. Carcinogenesis 1998, 19: 611-616.
27. Paschka AG, Butler R and Young CY. Induction of apoptosis in prostate cancer cell lines by the green tea component, (2)-epigallocatechin-3-gallate. Cancer Lett 1998, 130: 1-7.
28. Bours V, Bentires-Alj M, Hellin AC, Viatour P, Robe P, Delhalle S and Benoit V, et al. Nuclear factor-kB, cancer, and apoptosis. Biochem Pharmacol 2000, 60: 1085-1089.
29. Aggarwal BB. Apoptosis and nuclear factor-kB: A tale of association and dissociation. Biochem Pharmacol 2000, 60: 1033-1039.
30. Shammas MA, Neri P, Koley H, Batchu RB, Bertheau RC, Munshi V and Prabhala R, et al. Specific killing of multiple myeloma cells by (2)-epigallocatechin-3-gallate extracted from green tea: biologic activity and therapeutic implications. Blood 2006, 108: 2804-2810.
31. Richardson PG, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin D and Rajkumar SV, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 2003, 348: 2609-2617.
32. Golden EB, Lam PY, Kardosh A, Gaffney KJ, Cadenas E, Louie SG and Petasis NA, et al. Green tea polyphenols block the anticancer effects of bortezomib and other boronic acid-based proteasome inhibitors. Blood 2009, 113: 5927-5937.